• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Metformin does not improve the progression-free survival of stage IIIA or IIIB locally advanced non-small cell lung cancer patients compared to chemoradiation alone

byMeagan WidermanandMichael Pratte
August 7, 2021
in Chronic Disease, Oncology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Metformin, in addition to standard chemoradiation therapy, did not improve the progression-free survival, overall survival, local-regional recurrence, or distant metastasis occurrence compared to the control group of stage IIIA or IIIB locally advanced non-small cell lung cancer patients.

2. Serious adverse events were equally as common in the metformin and control groups, however, only 63.4% of participants could tolerate the metformin protocol.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Locally advanced (LA) non-small cell lung cancer (NSCLC) has a poor prognosis due to a lack of treatments. Some evidence exists that metformin has antineoplastic effects, including in NSCLC. The primary outcome of this study was progression-free survival (PFS), defined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria of LA-NSCLC patients treated with metformin. Additionally, the overall survival (OS), local-regional recurrence (LRR), distant metastasis (DM), and toxicity, defined using the Common Terminology Criteria for Adverse Events, were secondary outcomes. Stage IIIA or IIIB, LA-NSCLC patients were randomized to standard chemoradiation therapy (n = 81) or chemoradiation with metformin (n = 86), stratified performance by participant performance status, their histology, and stage. Most participants received their radiation and chemotherapy, but only 63.4% of the metformin group patients adhered fully to the metformin protocol. The one-year PFS and OS did not differ between the metformin and control group. While there were fewer deaths due to cancer in the metformin group, there were more unexplained or other-disease deaths. LRR and DM at 2 years did not differ in the metformin group compared to in the control group. Serious adverse events were equally as common in the metformin group as in the control group. Only 39% of participants were able to maintain the metformin dose as prescribed without adjustments, limiting this study’s power. The low adherence to the chemoradiation limits the generalizability of this study. Another limitation is that the trial wasn’t blinded since the control group did not receive a placebo.

Click to read the study in JAMA Oncology

Click to read an accompanying editorial in JAMA Oncology

Relevant Reading: Metformin for non-small cell lung cancer patients: Opportunities and pitfalls

RELATED REPORTS

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

In-Depth [randomized controlled trial]: This study, NRG-LU001, was a phase 2 study comparing metformin in addition to standard therapy to standard therapy alone at treating unresectable, stage IIIA or IIIB, LA-NSCLC. Patients who did not have cancer in the past 3 years, or a history of diabetes, who could perform at least light work (“performance status”, where light = 0 and heavy = 1) were enrolled. All patients received 60 Gy of radiation, weekly carboplatin and paclitaxel chemotherapy for 28 – 42 days, and then consolidative carboplatin and paclitaxel chemotherapy every 3 weeks for 2 cycles. Half of the patients were randomized to also receive 2000 mg metformin daily. The randomization was stratified by performance status, histology (SCC vs non-SCC), and stage (IIIA vs IIIB). Recurrence was monitored using regularly scheduled contrast-enhancement computed tomography (CT) or magnetic resonance imaging (MRI). At those same scheduled time points, the patient’s performance status and toxic response were measured. 170 patients from 79 institutions in the US, Canada, and Israel were recruited, who had demographics that were representative of NSCLC for age (64 years), sex (58.1% male), and ethnicity (82.0% White). While 3 were found to be ineligible after randomization, the metformin group (n = 86) and control group (n = 81) remained balanced for age, sex, and ethnicity, and all stratified variables. 86.0% of the metformin group and 92.6% of the control group received radiation. Many patients received their radiation and chemotherapy per protocol, with the bulk who did not receive therapy per protocol instead receiving appropriate minor deviations. 63.4% of the metformin group patients took the metformin throughout the trial. Patients were followed for an average of 27.7 months. PFS at one-year was not different between the metformin group (51.3%, 95% CI = 39.8%-61.7%) and the control group (60.4%, 95% CI = 48.5%-70.4%) (HR = 1.15, 95% CI = 0.77-1.73; P = 0.24). Shorter PFS was associated with higher stage (HR = 1.79; 95%CI = 1.19-2.69; P = 0.005), but not metformin treatment (HR = 1.20; 95% CI = 0.81-1.78; P = 0.36), histology (HR = 1.24; 95% CI = 0.83-1.85; P = 0.30), or performance status (HR = 0.70; 95% CI = 0.47-1.05; P = 0.09). A sensitivity analysis supported these results (HR = 1.09; 95%CI = 0.69-1.73; P = 0.36). OS, similarly, did not differ between the metformin (80.8%, 95% CI = 70.2%-87.9%) and control group (80.2%, 95% CI = 69.3%-87.6%) (HR = 1.03; 95% CI = 0.64-1.68; P = 0.89). Fewer deaths were due to disease in the metformin group (70.6%) compared to the control group (90.9%). At 2 years follow-up, there was no differences between the groups for LRR (HR = 0.91; 95% CI = 0.51-1.62; P = 0.75) or DM (HR = 1.29; 95% CI = 0.71-2.34; P = 0.41). Grade 3 adverse events also were not more frequent in the metformin group (65.8%) compared to the control group (68.0%). 1 metformin group patient and 4 control group patients experienced a grade 5 adverse event. Pneumonitis was uncommon in both the metformin (1.3%) and control (2.7%) group.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: metforminnon-small cell lung cancer (NSCLC)nsclc
Previous Post

Dose-tapering might be associated with increased risk of overdose and mental health crisis in patients prescribed long-term opioids

Next Post

2 Minute Medicine Rewind August 9, 2021

RelatedReports

Complement mutation linked to poor response to eculizumab
Oncology

Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer

May 23, 2022
#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
Next Post
Psychological impact of COVID-19 on health care workers in Singapore

2 Minute Medicine Rewind August 9, 2021

Provision of medically-tailored meals linked with lower admissions and medical spending

Plant‐centered diet and risk of incident cardiovascular disease during young to middle adulthood

Parents with poor sleep quality report sleep problems in kids

Napping associated with improved performance in memory tasks  

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.